Core Points - The company announced that its wholly-owned subsidiary, Ningbo Weierkaidi Medical Equipment Co., Ltd., has recently obtained a medical device registration change document issued by the National Medical Products Administration of China [2] Group 1 - The product, a disposable electric endoscopic linear cutting stapler, has completed the registration change for medical devices [2]

格隆汇11月21日丨戴维医疗(300314.SZ)公布，全资子公司宁波维尔凯迪医疗器械有限公司于近日取得 由国家药品监督管理局颁发的《中华人民共和国医疗器械变更注册（备案）文件》，公司产品一次性使 用电动腔镜用直线型切割吻合器完成了医疗器械产品注册变更。 ...

一、医疗器械注册证变更具体情况 | 序号 | 产品名称 | 注册证编号 | 注册分类 | 主要变更内容 | | --- | --- | --- | --- | --- | | 1 | 一次性使用电动腔镜 | 国械注准 20233011247 | Ⅲ类 | 因产品适用的强制性标 准更新，变更产品技术要 | | | 用直线型切割吻合器 | | | | | | | | | 求。 | 二、对公司的影响及风险提示 证券代码：300314 证券简称：戴维医疗 公告编号：2025-080 宁波戴维医疗器械股份有限公司 关于全资子公司医疗器械注册证变更的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 宁波戴维医疗器械股份有限公司（以下简称"公司"）全资子公司宁波 维尔凯迪医疗器械有限公司于近日取得由国家药品监督管理局颁发的《中华 人民共和国医疗器械变更注册（备案）文件》，公司产品一次性使用电动腔 镜用直线型切割吻合器完成了医疗器械产品注册变更，具体情况如下： 特此公告。 宁波戴维医疗器械股份有限公司 董事会 2025年11月21日 上述医疗器械注册证"产品技术要求"的变 ...

注册证编号：浙械注准20212080048 批准日期：2025年11月17日 证券代码：300314 证券简称：戴维医疗 公告编号：2025-079 宁波戴维医疗器械股份有限公司 关于医疗器械注册证变更的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 宁波戴维医疗器械股份有限公司（以下简称"公司"）于近日取得由 浙江省药品监督管理局颁发的1项《医疗器械变更注册（备案）文件》， 公司产品医用空气压缩机完成了医疗器械产品注册变更，具体情况如下： 产品名称：医用空气压缩机 3、注册证产品技术要求发生变更。 上述《医疗器械注册证》的变更，有利于进一步提升公司在儿产科保 育设备领域的核心竞争力，对公司未来经营将产生积极影响。上述产品的 实际销售情况取决于未来市场推广效果，公司目前尚无法预测其对公司未 来业绩的影响，敬请投资者注意投资风险。 特此公告。 宁波戴维医疗器械股份有限公司 董事会 2025年11月19日 变更内容： 1、型号规格：由"AC-200A、AC-200B"变更为"AC-100A、AC-100B、 AC-180A、AC-180B、AC-200A、A ...

格隆汇11月17日丨戴维医疗(300314.SZ)公布，公司因生产经营需要，对生产范围进行了变更，在原有 基础上增加了"第Ⅱ类：15-05-患者转运器械"，并于近日取得了由浙江省药品监督管理局颁发的变更后 的《医疗器械生产许可证》。 ...

Core Viewpoint - David Medical (300314.SZ) has expanded its production scope to include "Class II: 15-05 Patient Transport Equipment" and has recently obtained a revised Medical Device Manufacturing License from the Zhejiang Provincial Drug Administration [1] Group 1 - The company has made changes to its production range to meet operational needs [1] - The newly added category focuses on patient transport equipment, indicating a strategic expansion in its product offerings [1] - The approval from the Zhejiang Provincial Drug Administration signifies regulatory compliance and enhances the company's operational capabilities [1]

证券代码：300314 证券简称：戴维医疗 公告编号：2025-078 宁波戴维医疗器械股份有限公司 关于变更医疗器械生产许可证的公告 统一社会信用代码：91330200610257495J 企业名称：宁波戴维医疗器械股份有限公司 法定代表人：陈再宏 企业负责人：陈再宏 住所：浙江省宁波市象山县石浦科技园区科苑路2号 生产地址：浙江省宁波市象山县石浦科技园区科苑路2号 生产范围：第Ⅲ类：08-03-急救设备；第Ⅱ类：02-12-手术器械-穿刺 导引器，02-13-手术器械-吻（缝）合器械及材料，07-03-生理参数分析测 量设备，07-04-监护设备，08-03-急救设备，08-05-呼吸、麻醉、急救设备 辅助装置，08-07-医用供气排气相关设备，09-02-温热（冷）治疗设备/器 具，09-03-光治疗设备，14-06-与非血管内导管配套用体外器械，14-15- 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 病人护理防护用品，15-05-患者转运器械*** 宁波戴维医疗器械股份有限公司（以下简称"公司"）因生产经营需要， 对生产范围进行了变更，在原有基础 ...

Core Viewpoint - David Medical stated that as of November 10, 2025, the total number of shareholders is approximately 19,800 [2] Summary by Category - **Company Information** - The total number of shareholders for David Medical is projected to be around 19,800 by November 10, 2025 [2]

Core Points - The stock price of David Medical increased by 2.06% on November 10, reaching 13.87 CNY per share, with a market capitalization of 3.995 billion CNY [1] - The company has seen a year-to-date stock price increase of 24.14% and a net inflow of main funds amounting to 1.0117 million CNY [1] - David Medical's main business includes the research, production, and sales of infant care equipment, with revenue composition of 51.93% from obstetric and pediatric care equipment and 45.88% from minimally invasive surgical instruments [1] Financial Performance - For the period from January to September 2025, David Medical reported a revenue of 393 million CNY, a year-on-year decrease of 2.55%, while the net profit attributable to shareholders increased by 14.71% to 72.6178 million CNY [2] - Cumulative cash dividends since the A-share listing amount to 342 million CNY, with 120 million CNY distributed over the past three years [3] Shareholder Information - As of October 31, 2025, the number of shareholders decreased by 1.49% to 19,900, with an average of 7,223 circulating shares per person, an increase of 1.51% [2] - The top ten circulating shareholders include new entrants such as the Medical Device ETF and Baodao Jiuhang Mixed A, holding 712,000 shares and 545,900 shares respectively [3]

Core Viewpoint - David Medical announced the election of Chen Zaihong as the chairman of the board [2] Company Summary - The announcement was made on the evening of November 3 [2]